Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Stats
Total: 33 #1
CompanyExact Sciences Corporation
IndustryMedical Laboratories & Research
Market Cap962.82MEPS (ttm)-1.61
P/E-EPS this Y-81.20%
Forward P/E-EPS next Y13.80%
PEG-EPS past 5Y-34.90%
P/S69.27EPS next 5Y25.00%
P/B3.96EPS Q/Q-83.30%
Dividend-Sales Q/Q-
Insider Own1.10%Inst Own93.40%
Insider Trans-3.05%Inst Trans0.10%
Short Float27.44%EarningsOct 27/b
Analyst Recom2.00Target Price29.67
Avg Volume2.03M52W Range9.80 - 32.85
Oct-08-15Reiterated Wedbush Neutral $18 → $7
Oct-08-15 11:53AMExact Sciences: Make It Stop! at
Oct-08-15 11:41AM11:41 am EXACT Sciences (-26%) extends recent losses, falls to multi-year low following disappointing USPSTF draft recommendation for Cologuard
Oct-08-15 09:15AMHow Obamacare Cost One Small Company Nearly Half Its Market Value at Forbes
Oct-06-15 09:32PMTrending Now: EXAS
Oct-06-15 04:04PMThe 52-Week Low Club for Tuesday
Oct-06-15 03:01PMBiotechs take a beating
Oct-06-15 02:34PMExact Sciences: Half the Stock It Used to Be at
Oct-06-15 01:35PMExact Sciences shares plunge after product snubbed in draft recommendations at
Oct-06-15 12:38PMWhat's Wrong With Health Care? at
Oct-06-15 12:03PMThis Metric Says One Of These Two Stocks in Red Is a Buy at Insider Monkey
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with MAYO Foundation for Medical Education and Research for developing tests to detect other gastrointestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Megan William J.SVP, FinanceAug 26Option Exercise0.0015,000046,807Aug 28 06:25 PM
Conroy Kevin TPresident and CEOJul 27Sale24.0411,386273,719257,335Jul 28 04:19 PM
ARORA MANEESHCOOJul 27Sale24.049,332224,341132,248Jul 28 04:22 PM
LIDGARD GRAHAM PETERChief Science OfficerJul 27Sale24.0412,579302,399205,334Jul 28 04:25 PM
Conroy Kevin TPresident and CEOJul 25Option Exercise0.0025,0000268,721Jul 28 04:19 PM
CompanyCardiovascular Systems Inc.
IndustryMedical Appliances & Equipment
Market Cap540.14MEPS (ttm)-1.04
P/E-EPS this Y16.80%
Forward P/E-EPS next Y58.20%
PEG-EPS past 5Y8.50%
P/S2.98EPS next 5Y32.33%
P/B3.79EPS Q/Q12.90%
Dividend-Sales Q/Q22.50%
Insider Own3.30%Inst Own73.00%
Insider Trans-11.85%Inst Trans0.14%
Short Float8.81%EarningsOct 28/a
Analyst Recom1.10Target Price43.89
Avg Volume385.97K52W Range14.91 - 41.28
Oct-08-15Downgrade Leerink Partners Outperform → Mkt Perform
Oct-08-15Downgrade Needham Strong Buy → Buy $37 → $18
Oct-08-15Reiterated Dougherty & Company Buy $50 → $32
Oct-08-15 01:07PMCardiovascular Systems (CSII) Stock Tanks on Preliminary First Quarter Results at TheStreet
Oct-08-15 11:21AMCardiovascular Systems Inc is Crashing Today: Here's Why at Motley Fool
Oct-08-15 09:48AM9:48 am Cardiovascular Systems (-20%) bounces after falling to near 3 year low after Q1 warning
Oct-07-15 04:05PMCARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition
Oct-07-15 04:00PMCardiovascular Systems Reports Preliminary Fiscal First-Quarter Financial Results Business Wire
Sep-25-15 04:22PMRobbins Arroyo LLP Is Investigating the Officers and Directors of Cardiovascular Systems, Inc. (CSII) on Behalf of Shareholders PR Newswire
Sep-22-15 11:33AMFaruqi & Faruqi, LLP is Investigating Cardiovascular Systems Inc. (CSII) on Behalf of its Shareholders PR Newswire
Sep-14-15 04:21PMCARDIOVASCULAR SYSTEMS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases in the United States. It offers peripheral arterial disease products, including Stealth 360 Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Diamondback 360 60cm Peripheral OAS access device, and the 4 Diamondback 360 French 1.25 Peripheral OAS access device products for treating a range of plaque types, such as calcified plaque, in leg arteries both above and below the knee and address many of the limitations associated with existing surgical, catheter, and pharmacological treatment alternatives, as well as Diamondback 360 Coronary OAS, a catheter-based platform to facilitate stent delivery in patients with coronary artery disease. The company sells its products directly to hospitals or office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Thatcher Robert J.Chief Healthcare Policy Off'rOct 02Option Exercise12.3764,700800,339191,678Oct 06 08:48 PM
Thatcher Robert J.Chief Healthcare Policy Off'rOct 02Sale16.3164,7001,055,082126,978Oct 06 08:48 PM
Martin DavidPresident and CEOSep 02Sale23.134,14195,772458,818Sep 03 04:38 PM
Martin DavidPresident and CEOSep 01Sale23.9915,505371,909462,959Sep 03 04:38 PM
BETTERLEY LAURENCE LChief Financial OfficerSep 01Sale23.969,597229,911191,414Sep 03 04:39 PM
CompanyParagon Shipping Inc.
Market Cap6.44MEPS (ttm)-3.95
P/E-EPS this Y-66.40%
Forward P/E-EPS next Y-35.50%
PEG-EPS past 5Y-16.30%
P/S0.14EPS next 5Y-
P/B0.05EPS Q/Q-98.00%
Dividend-Sales Q/Q-65.90%
Insider Own27.85%Inst Own8.90%
Insider Trans0.00%Inst Trans-
Short Float1.54%EarningsSep 01/a
Analyst Recom2.00Target Price2.25
Avg Volume89.19K52W Range0.25 - 3.86
Sep-04-15 05:02PMParagon Shipping Inc. Announces At-The-Market Offering Of Up To $4.0 Million Of Common Shares PR Newswire
Sep-02-15 12:20PMEdited Transcript of PRGN earnings conference call or presentation 2-Sep-15 1:00pm GMT
Sep-01-15 04:01PMParagon Shipping Inc. Reports Second Quarter And Six Months Ended June 30, 2015 Results PR Newswire
Sep-01-15 07:07AMQ2 2015 Paragon Shipping Inc Earnings Release - After Market Close
Aug-28-15 04:01PMParagon Shipping Announces Date For The Release Of Second Quarter And Six Months Ended June 30, 2015 Results, Conference Call And Webcast PR Newswire
Jul-21-15 07:00AMGreek Crisis Spreads to Its Domestic Business Accesswire
Paragon Shipping Inc. provides shipping transportation services worldwide. It engages in the ocean transportation of drybulk cargoes, including commodities, such as iron ore, coal, grain, and other materials. As of December 31, 2014, the company's fleet consisted of eight Panamax drybulk carriers, two Ultramax drybulk carriers, two Supramax drybulk carriers, and four Handysize drybulk carriers with an aggregate capacity of 980,380 dwt. Paragon Shipping Inc. was founded in 2006 and is based in Voula, Greece.
CompanyCadiz Inc.
IndustryWater Utilities
Market Cap71.46MEPS (ttm)-1.19
P/E-EPS this Y21.20%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-0.40%
P/S178.65EPS next 5Y-
P/B-EPS Q/Q-21.40%
Dividend-Sales Q/Q245.50%
Insider Own1.40%Inst Own76.10%
Insider Trans43.40%Inst Trans1.13%
Short Float19.62%EarningsNov 05
Analyst Recom-Target Price-
Avg Volume156.73K52W Range4.00 - 11.93
Oct-07-15 03:36PMThe Cadiz water scheme: How political juice kept a bad idea alive for years at Los Angeles Times
Oct-05-15 01:38PMHedge Fund Metric Says These Two Stocks Deep In The Red Today Could Be Good Buys at Insider Monkey
Oct-05-15 09:15AMCadiz Inc. Announces Guidance from US Bureau of Land Management Regarding Cadiz Water Projects Proposed Use of a Railroad ROW Business Wire
Sep-17-15 10:44AMCadiz, Inc. Earnings Q2, 2015
Sep-08-15 04:00PMCadiz Inc. to Present at Rodman & Renshaw 17th Annual Global Investment Conference GlobeNewswire
Aug-31-15 09:30AMEleven Amicus Curiae Briefs Filed in Support of the Cadiz Water Project GlobeNewswire
Aug-15-15 01:04PMCADIZ INC Financials
Aug-12-15 01:06PMAmerican Water Works Co., Inc. Earnings Q2*, 2015
Aug-10-15 11:55AMCadiz Inc., ATEC Systems Associates Inc. and CH2M Execute Strategic Alliance Agreement to Provide Treatment for Chromium-6 in Drinking Water Sources Business Wire
Cadiz Inc. operates as a land and water resource development company in the United States. It engages in the water resource, and land and agricultural development activities in San Bernardino County properties. The company owns approximately 34,000 acres of land and the subsurface strata, including unsaturated soils and appurtenant water rights in the Cadiz and Fenner valleys of eastern San Bernardino County; and approximately 11,000 additional acres in the eastern Mojave Desert in eastern San Bernardino County. It is also involved in the cultivation of lemons and grapes/raisins, and spring and fall plantings of vegetables on the Cadiz Valley properties. The company has a strategic alliance with ATEC Systems Associates, Inc. and CH2M for the use of a technology for the treatment and removal of Chromium-6 from drinking water supplies. Cadiz Inc. was founded in 1983 and is based in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Water Asset Management LLC10% OwnerOct 01Buy7.557,40055,8702,437,560Oct 05 04:01 PM
Water Asset Management LLC10% OwnerSep 29Buy7.397,90058,4042,430,160Oct 01 04:02 PM
Water Asset Management LLC10% OwnerJul 15Buy9.205,20047,8402,422,260Jul 15 05:10 PM
Water Asset Management LLC10% OwnerJul 14Buy9.6110,00096,1002,417,060Jul 15 05:10 PM
Water Asset Management LLC10% OwnerJul 13Buy9.3415,000140,1002,407,060Jul 15 05:10 PM
CompanySuperconductor Technologies Inc.
IndustrySemiconductor - Integrated Circuits
Market Cap9.79MEPS (ttm)-0.64
P/E-EPS this Y62.60%
Forward P/E13.45EPS next Y107.10%
PEG-EPS past 5Y39.40%
P/S32.64EPS next 5Y-
P/B1.12EPS Q/Q-
Dividend-Sales Q/Q-5.30%
Insider Own8.40%Inst Own38.10%
Insider Trans6.40%Inst Trans8.65%
Short Float5.56%EarningsNov 12/b
Analyst Recom3.00Target Price-
Avg Volume166.93K52W Range0.47 - 3.10
Sep-30-15 10:37AMSuperconductor Technologies, Inc. Earnings Q2, 2015
Aug-27-15 06:30AMSuperconductor Technologies to Present at the 2015 European Conference on Applied Superconductivity Sept. 6th to 10th GlobeNewswire
Aug-21-15 04:47PMEdited Transcript of SCON earnings conference call or presentation 11-Aug-15 3:00pm GMT
Aug-13-15 08:10PM10-Q for Superconductor Technologies, Inc. at Company Spotlight
Aug-11-15 11:00AMSuperconductor Technologies Inc Earnings Call scheduled for 11:00 am ET today
Aug-11-15 07:07AMQ2 2015 Superconductor Technologies Inc Earnings Release - Before Market Open
Aug-11-15 06:31AMSUPERCONDUCTOR TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
Superconductor Technologies Inc. develops and commercializes high temperature superconductor (HTS) materials and related technologies in the United States. The company is leveraging its technologies, including HTS materials and cryogenics to produce HTS Conductus wire for applications in the electrical grid and equipment platforms that use electrical circuits. Superconductor Technologies Inc. was founded in 1987 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kopp LeRoy C10% OwnerSep 08Buy1.0380,00082,480113,000Sep 10 06:13 PM
Kopp LeRoy C10% OwnerJun 10Buy1.0412,00012,51633,000Jun 12 05:09 PM
CompanyMirna Therapeutics, Inc.
Market Cap107.25MEPS (ttm)-274.62
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
Dividend-Sales Q/Q-
Insider Own-Inst Own-
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume331.12K52W Range6.28 - 7.99
Oct-06-15 11:13AM11:13 am Mirna Therapeutics closes both its IPO of 6.25 mln shares at $7/share, and a concurrent private placement of 2,395,010 common shares at $7/share with the Cancer Prevention and Research Institute of Texas
Oct-06-15 11:11AMMirna Therapeutics Announces Closing of Initial Public Offering and Concurrent Private Placement with CPRIT Business Wire
Oct-04-15 09:25AM10 IPOs on Calendar for Week Ahead at 24/7 Wall St.
Oct-02-15 01:00AMU.S. IPO market seen shaken but not shut Reuters
Oct-01-15 04:07PMAustin biotech company makes Wall Street debut at
Oct-01-15 07:00AMMirna Therapeutics Announces Pricing of Its Initial Public Offering Business Wire
Developing microRNA replacement therapies for liver cancer.
CompanyThe Spectranetics Corporation
IndustryMedical Appliances & Equipment
Market Cap503.63MEPS (ttm)-1.50
P/E-EPS this Y-277.80%
Forward P/E-EPS next Y35.30%
PEG-EPS past 5Y-19.00%
P/S2.09EPS next 5Y15.00%
P/B3.69EPS Q/Q-30.80%
Dividend-Sales Q/Q41.50%
Insider Own1.60%Inst Own93.80%
Insider Trans1.76%Inst Trans0.06%
Short Float16.08%EarningsOct 22/a
Analyst Recom1.70Target Price25.05
Avg Volume923.01K52W Range11.33 - 37.04
Oct-08-15 07:30AMSpectranetics to Hold 2015 Third Quarter Financial Results Conference Call on October 22, 2015 GlobeNewswire
Oct-07-15 06:37PMSHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving The Spectranetics Corporation and a Lead Plaintiff Deadline of October 26, 2015 - SPNC GlobeNewswire
Oct-02-15 10:46AMThe Spectranetics Corp. Earnings Q2, 2015
Sep-30-15 10:43PMINVESTOR DEADLINE: Goldberg Law PC Reminds Investors With Losses In Spectranetics Corporation Of October 26, 2015 Deadline Business Wire
Sep-30-15 09:30AMQT Vascular Announces Positive Outcome in Spectranetics/AngioScore Patent Trial PR Newswire
Sep-30-15 09:15AM9:15 am Spectranetics reports that a Northern District of California has found against its subsidiary, AngioScore with regard to patent infringement claims
Sep-30-15 09:04AMSPECTRANETICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-30-15 09:00AMJury in Federal Court in California Finds Against AngioScore's Patent Infringement Claims GlobeNewswire
The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JENNINGS WILLIAM CDirectorAug 11Buy15.9710,000159,71157,764Aug 13 10:28 AM
Drake Scott WilliamPresident, CEOAug 10Option Exercise0.0012,500094,015Aug 12 05:27 PM
Matin ShahriarChief Operating OfficerJul 29Option Exercise3.4520,31870,04464,002Jul 30 10:55 AM
Bridges Kimberly McIntoshSr VP, Sales & Mktg, VIJul 29Buy16.803,00050,4004,431Jul 30 04:47 PM
Drake Scott WilliamPresident, CEOJul 28Option Exercise5.6326,643150,00081,515Jul 28 12:41 PM
TickerNRX [NASD]
CompanyNephroGenex, Inc.
IndustryDrugs - Generic
Market Cap32.32MEPS (ttm)-2.39
P/E-EPS this Y-202.80%
Forward P/E-EPS next Y15.20%
PEG-EPS past 5Y0.00%
P/S-EPS next 5Y-
P/B3.25EPS Q/Q-18.00%
Dividend-Sales Q/Q-
Insider Own55.86%Inst Own62.00%
Insider Trans0.00%Inst Trans20.14%
Short Float1.27%EarningsNov 12/a
Analyst Recom2.00Target Price12.00
Avg Volume61.49K52W Range3.03 - 17.98
Oct-05-15 06:10AMNEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-30-15 08:00AMNephroGenex to Present at the 2015 Aegis Growth Conference Business Wire
Sep-02-15 06:03AMNEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-01-15 09:45AMNephroGenex: A Significant Unmet Medical Need
Sep-01-15 07:35AMCoverage initiated on NephroGenex by H.C. Wainwright
Aug-31-15 08:45AMAs Diabetes Becomes an Epidemic, Patients Seek the Best Treatment Options Accesswire
Aug-31-15 08:00AMNephroGenex To Participate In Two Healthcare Conferences In September Business Wire
Aug-26-15 01:04PMNEPHROGENEX, INC. Financials
Aug-12-15 04:12PMNephroGenex Reports Second Quarter 2015 Financial Results Business Wire
NephroGenex, Inc., a drug development company, focuses on developing novel therapies for kidney disease. It develops Pyridorin (pyridoxamine dihydrochoride), a therapeutic agent, which is in Phase III clinical study for the treatment of diabetic nephropathy. The company also engages in studying the application of an intravenous formulation of Pyridorin to specific types of acute kidney injury in patients where pathogenic oxidative chemistries have been identified as a contributing factor to the severity of this condition. NephroGenex, Inc. was founded in 2004 and is headquartered in Raleigh, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rho Ventures V, L.P.10% OwnerJan 06Sale9.9020,941207,3391,052,966Jan 06 05:55 PM
Rho Ventures V, L.P.10% OwnerJan 05Sale10.54164,9191,738,0651,073,907Jan 06 05:55 PM
Rho Ventures V, L.P.10% OwnerJan 02Sale10.8388,000953,2071,238,826Jan 06 05:55 PM
Peterson BobVP of Prod. Dev. & Reg. Aff's.Nov 25Buy4.202,0008,4002,000Nov 25 04:07 PM
CompanyAdaptimmune Therapeutics plc
CountryUnited Kingdom
Market Cap618.67MEPS (ttm)-0.96
P/E-EPS this Y-33.30%
Forward P/E-EPS next Y-46.20%
PEG-EPS past 5Y0.00%
P/S147.30EPS next 5Y-11.40%
P/B1.14EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own29.60%
Insider Trans-Inst Trans-
Short Float12.44%Earnings-
Analyst Recom1.80Target Price22.00
Avg Volume237.98K52W Range8.38 - 21.57
Oct-07-15 09:34AMAdaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015 GlobeNewswire
Oct-07-15 09:14AMAdaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015 GlobeNewswire
Oct-06-15 07:01AMAdaptimmune Announces New Research and Development Facility in Oxfordshire GlobeNewswire
Oct-06-15 07:00AMAdaptimmune Announces New Research and Development Facility in Oxfordshire GlobeNewswire
Sep-28-15 08:00AMAdaptimmune to Participate in the Leerink Partners Inaugural Immuno-Oncology Roundtable GlobeNewswire
Sep-14-15 03:22PMAdaptimmune to Participate in Two Upcoming Investor Conferences GlobeNewswire
Sep-09-15 08:30AMAdaptimmune Announces Expansion of Senior Team to Augment Clinical Expertise and Support Growth GlobeNewswire
Sep-03-15 08:45AMAdaptimmune to Participate in the 22nd Annual BioCentury 'NewsMakers in the Biotech Industry' Conference GlobeNewswire
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
CompanyO2Micro International Ltd.
CountryCayman Islands
IndustryDiversified Electronics
Market Cap48.40MEPS (ttm)-0.56
P/E-EPS this Y17.90%
Forward P/E-EPS next Y54.10%
PEG-EPS past 5Y-49.60%
P/S0.84EPS next 5Y19.00%
P/B0.48EPS Q/Q8.30%
Dividend-Sales Q/Q-15.50%
Insider Own9.76%Inst Own47.70%
Insider Trans0.00%Inst Trans4.14%
Short Float0.27%EarningsOct 29/b
Analyst Recom1.70Target Price4.71
Avg Volume49.01K52W Range1.85 - 2.82
Oct-07-15 08:30AMO2Micro to Announce Third Quarter 2015 Results GlobeNewswire
Oct-06-15 04:00PMOIIM: The Chinese Consumer is Not Buying TVs Zacks Small Cap Research
Oct-06-15 08:31AM8:31 am O2Micro lowers Q3 sales guidance; reaffirms gross margin
Oct-06-15 08:30AMO2Micro Revises Third Quarter 2015 Financial Guidance GlobeNewswire
Sep-22-15 08:30AMO2Micro's Charge Pump System Issued Patent GlobeNewswire
Aug-31-15 09:55AMO2Micro International Ltd. Earnings Q2, 2015
Jul-30-15 05:44PMEdited Transcript of OIIM earnings conference call or presentation 30-Jul-15 1:00pm GMT
O2Micro International Limited, together with its subsidiaries, designs, develops, and markets integrated circuits and solutions for power management components and systems. It provides analog and mixed-signal integrated circuit products that manage and provide LCD and LED lighting; control and monitor battery charging and discharging in portable electronic devices and automobiles; perform DC/DC and AC/DC conversion; and provide select and switch functionality between power sources. The company's products are primarily used in the consumer electronics, computer, industrial, communication, and automotive markets for applications, including LCD and LED monitors, LCD and LED televisions, notebook and tablet computers, low/zero emission vehicles, mobile phones, energy efficient technology relating to batteries, LED lighting, and portable electronics devices. O2Micro International Limited sells its products through direct sales force, independent sales representatives, and distributors to OEMs, ODMs, and module makers in Asia, Europe, and North America. It also licenses its proprietary intellectual property to third parties; and provides design and engineering support services. The company was founded in 1995 and is based in George Town, the Cayman Islands.
1 2 3 4 next